Xeljanz (Tofacitinib) Price by US State (2026 Analysis)
Estimated Xeljanz (Tofacitinib) retail and out-of-pocket cost (per month supply) across all 50 US states, compared with international pharmaceutical benchmarks in India (approx. $150). US state figures represent modeled healthcare-cost adjustments from the national baseline ($6,000).
State Price Variations for Xeljanz (Tofacitinib)
51 States & TerritoriesComplete State Cost Table
| State | US Price (Est.) | India Price | You Save |
|---|---|---|---|
| Alabama | $5,400 | $150 | $5,250 |
| Alaska | $7,680 | $150 | $7,530 |
| Arizona | $6,000 | $150 | $5,850 |
| Arkansas | $5,280 | $150 | $5,130 |
| California | $7,800 | $150 | $7,650 |
| Colorado | $6,480 | $150 | $6,330 |
| Connecticut | $7,320 | $150 | $7,170 |
| Delaware | $6,300 | $150 | $6,150 |
| Florida | $6,120 | $150 | $5,970 |
| Georgia | $5,760 | $150 | $5,610 |
| Hawaii | $7,920 | $150 | $7,770 |
| Idaho | $5,700 | $150 | $5,550 |
| Illinois | $6,360 | $150 | $6,210 |
| Indiana | $5,700 | $150 | $5,550 |
| Iowa | $5,580 | $150 | $5,430 |
| Kansas | $5,520 | $150 | $5,370 |
| Kentucky | $5,400 | $150 | $5,250 |
| Louisiana | $5,580 | $150 | $5,430 |
| Maine | $6,360 | $150 | $6,210 |
| Maryland | $7,080 | $150 | $6,930 |
| Massachusetts | $7,680 | $150 | $7,530 |
| Michigan | $5,880 | $150 | $5,730 |
| Minnesota | $6,360 | $150 | $6,210 |
| Mississippi | $5,160 | $150 | $5,010 |
| Missouri | $5,520 | $150 | $5,370 |
| Montana | $5,880 | $150 | $5,730 |
| Nebraska | $5,640 | $150 | $5,490 |
| Nevada | $6,120 | $150 | $5,970 |
| New Hampshire | $6,720 | $150 | $6,570 |
| New Jersey | $7,320 | $150 | $7,170 |
| New Mexico | $5,640 | $150 | $5,490 |
| New York | $7,800 | $150 | $7,650 |
| North Carolina | $5,760 | $150 | $5,610 |
| North Dakota | $5,820 | $150 | $5,670 |
| Ohio | $5,760 | $150 | $5,610 |
| Oklahoma | $5,340 | $150 | $5,190 |
| Oregon | $6,600 | $150 | $6,450 |
| Pennsylvania | $6,240 | $150 | $6,090 |
| Rhode Island | $6,840 | $150 | $6,690 |
| South Carolina | $5,700 | $150 | $5,550 |
| South Dakota | $5,700 | $150 | $5,550 |
| Tennessee | $5,520 | $150 | $5,370 |
| Texas | $6,000 | $150 | $5,850 |
| Utah | $6,000 | $150 | $5,850 |
| Vermont | $6,720 | $150 | $6,570 |
| Virginia | $6,360 | $150 | $6,210 |
| Washington | $7,080 | $150 | $6,930 |
| Washington, D.C. | $8,040 | $150 | $7,890 |
| West Virginia | $5,400 | $150 | $5,250 |
| Wisconsin | $6,000 | $150 | $5,850 |
| Wyoming | $5,880 | $150 | $5,730 |
Frequently Asked Questions: Xeljanz (Tofacitinib) Pricing
Why do Xeljanz (Tofacitinib) prices differ across US states?+
Prescription drug prices in the US vary by state due to differing pharmacy dispensing fee regulations, state tax laws, regional wholesale distribution costs, and varying health insurance plan coverage formularies. Out-of-pocket prices can differ by hundreds of dollars even between neighboring states.
How does the US price of Xeljanz (Tofacitinib) compare to international prices?+
In the United States, Xeljanz (Tofacitinib) averages approximately $6,000 per month supply. In India, certified manufacturers produce equivalent formulations and authorized generics for about $150 per month supply — saving patients up to 90%+ without compromising therapeutic equivalence.
Are generic or biosimilar versions of Xeljanz (Tofacitinib) available?+
Depending on patent expiry schedules, authorized generic alternatives and international equivalents may be accessible through licensed personal importation channels.
Other Autoimmune Medications
Enbrel (Etanercept)
Enbrel (etanercept) is a biologic TNF-inhibitor injected to treat rheumatoid arthritis, psoriasis, and other autoimmune conditions. Approved biosimilars in India bring the monthly cost down by roughly 90% versus the US price.
Humira (Adalimumab)
Humira (adalimumab) is a biologic TNF-inhibitor given by subcutaneous injection to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. As one of the best-selling drugs in the world, its US cost is extremely high. India's availability of approved adalimumab biosimilars brings the monthly cost down by roughly 90%.
Stelara (Ustekinumab)
Stelara (ustekinumab) is a biologic used for psoriasis, psoriatic arthritis, and Crohn's disease, given as periodic injections or infusions. Each US dose costs many thousands of dollars; in India the per-dose price is far lower.